JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

The most recent version of this article was published on 1 August 2008

J Clin Pathol. Published Online First: 22 April 2008. doi:10.1136/jcp.2008.056093
Copyright © 2008 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
jcp.2008.056093v1
61/8/914    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Leuverink, E.
Right arrow Articles by Stewart, C. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leuverink, E.
Right arrow Articles by Stewart, C. J.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Ovarian Cancer

Histopathology

Prognostic value of mitotic counts and Ki-67 immunoreactivity in adult-type granulosa cell tumour of the ovary

Esther Leuverink 1, Barbara A Brennan 1, Maxine L Crook 2, Dorota Doherty 3, Ian G Hammond 4, Sukeerat Ruba 1 and Colin JR Stewart 1*

1 Department of Histopathology, King Edward Memorial Hospital, Australia
2 Department of Hitopathology, King Edward Memorial Hospital, Australia
3 School of Women's and Infants Health, University of Western Australia, Australia
4 Department of Gynaecological Oncology, King Edward Memorial Hospital, Australia

* To whom correspondence should be addressed. E-mail: colin.stewart{at}health.wa.gov.au.

Accepted 4 April 2008


*   Abstract

Aims: The identification of reliable prognostic factors in patients with stage 1 adult-type granulosa cell tumour (GCT) has proved problematic. Some reports have suggested that proliferation indices may be of value but the data are conflicting and the methods of assessment often poorly defined. In this study we have assessed mitotic activity and Ki-67 immunohistochemistry in a series of GCT using carefully specified methodology and have correlated the findings with clinico-pathological findings.

Methods: Tumour proliferation was assessed in 38 primary GCT by counting mitotic figures (MF) in 50 high power fields (x500 magnification) with results expressed as a mean count/ 2mm2 standardised area. The number of MF and Ki-67 immunoreactive cells/10,000 tumour cells was also assessed using an ocular cell counting graticule. The results were correlated with tumour stage at presentation and with the development of tumour recurrence.

Results: Twenty-nine patients were stage 1 at presentation while 9 patients had high stage disease (extra-ovarian spread). Nine patients with initial stage 1 disease developed metastases while 20 patients had no evidence of recurrence over a mean follow up period of 11.1 years. There was no significant correlation between any of the proliferation indices and with clinical outcomes.

Conclusions: These results suggest that proliferation assessment is of limited value in the pathological assessment of GCT. Future studies should carefully specify the methods of assessing cell proliferation to ensure a reliable comparison of results.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.